PrEP

At the virtual 2020 ASHP Midyear Clinical Meeting and Exhibition, Elyse Tung, PharmD, BCACP, discussed key counseling points for pharmacists to address with patients when prescribing and managing PrEP.

Additional non-oral options could provide more manageable forms of PrEP treatment for patients, potentially increasing global uptake of PrEP in the future.

Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).

Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).

This activity is supported by an educational grant from Janssen Therapeutics, division of Janssen Products, LP.

Top news of the week from Pharmacy Times.

Less than 10% of the people who should be taking pre-exposure prophylaxis for HIV are taking the medications.

Insurance companies are currently investigating the option of modifying which medications they will cover for HIV pre-exposure prophylaxis (PrEP) therapy, with broad implications for patient access.

Learn how retail or specialty pharmacy distribution can affect access to these important drugs.

Although the use of preexposure prophylaxis against HIV has increased across the United States in recent years, the rise in costs across the health care system has yet to be fully catalogued.

Men at particular risk for HIV are very likely to consistently take preventative medication during vacations when their odds of contracting the virus are higher, according to a study conducted by researchers at the University of Pittsburgh.

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study has played a key role in helping the health care industry look closer at the disproportionate risk of comorbidities, such as chronic liver and kidney disease, physical function impairment and frailty, premature reproductive aging, and cancer in patients with HIV.

Regional and state access assistance, improved research and collaboration, and individualized options for patients are key factors in adherence to PrEP.

The new report intends to change the practices in the HIV/coinfections research community so that women, providers, and policy makers can make evidence-based decisions regarding the use of medications during pregnancy.

Event-driven PrEP is initiated 2-24 hours ahead of sexual activity, but the most common method of HIV PrEP is a daily oral pill.

Small, automated financial incentives improved retention in care and viral suppression among adults with HIV starting antiretroviral therapy.

Results were announced at the virtual 23rd International AIDS Conference.

In developing countries with overcrowded hospitals, community pharmacies can relive burden, help patients adhere to their regimen, thus offering a viable alternative to patients who need to maintain their medication and keep stable.

PrEP-AP is intended to lower out-of-pocket costs for both uninsured and insured people who are eligible for PrEP services such as laboratory tests.

When taken daily, PrEP is highly effective for preventing HIV from sex or injection drug use.

New research indicates that even with effective antiretroviral treatment, HIV may still affect the central nervous system.

Remdesivir, the investigational drug for the treatment of the coronavirus disease 2019 (COVID-19), will be sold for $390 per vial.

Although researchers know that HIV enters the brain within 8 days of infection, less is known about whether HIV-infected brain cells can release the virus, letting it migrate from the brain back into the body to infect other tissues.

Access and adherence to pre-exposure prophylaxis is vital in eradicating the HIV epidemic in the United States.

Closing these gaps in care could improve access for those worse affected by HIV in developing countries.